Ozempic (semaglutide) is a GLP-1 receptor agonist licensed for type 2 diabetes treatment in the UK, administered subcutaneously once weekly
& Gresser, U
The medication works by mimicking the naturally occurring GLP-1 hormone, which enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite
On the other hand, 20% of the Ozempic trial participants felt nausea, and 10% indicated instances of vomiting , both of which are common symptoms associated with gastroparesis
It's the virus, or the parasite, or the bacterial infection, or whatever it might be, that first hit that causes this inflammatory cascade that then causes your more chronic conditions of ME/CFS and POTS
Potential pathways include improvements in endothelial function, reductions in blood pressure, anti-inflammatory effects, and direct myocardial protection, all of which have been described with GLP-1RA therapy independent of weight change [12,13,14]